Enable JavaScript to visit this website.

產品資訊

膽固清<sup>®</sup> Lipitor<sup>®</sup>

通用名稱: 阿托伐他汀鈣 (結晶型配方) Atorvastatin Calcium (Crystalline Form)

劑量: 10毫克、20毫克、40毫克、80毫克

膽固清®經多過400個臨床研究驗証、8萬多名病人參與研究及超過20年的臨床經驗,至今累積的病人年達2億5千萬年1,除適合關注膽固醇人士服用,更被證實有助心血管高危族(高血壓、糖尿病及確診冠心病患者)減低心血管風險2。目前為英國國家健康與照顧卓越研究院3、美國心臟協會4及歐洲心臟病協會5多個國際指引的第一線藥物。根據一項本地醫生調查,膽固清®同時被選為「最多醫生為自己及家人選用」及「全港最多醫生認為膽固清最安全、有效」6

資料來源
  1. Lipitor Core Claims Document. Pfizer Corporation Hong Kong Limited: Version 4, February 2016. Data on file.
  2. Lipitor® (atorvastatin) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version January 2019.
  3. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. Available at: nice.org.uk/guidance/cg181. Accessed July 2019.
  4. Stone NJ, et al. Circulation 2014;129(Suppl 2):S1-S45.
  5. Catapano AL, et al. Eur Heart J 2016;37:2999-3058.
  6. Ipsos Healthcare 2016 Brand Preference Study Interviewed 200 HCPs (Cardiologists, Endocrinologists, Nephrologists, Neurologists and GP/OM/GOPC) in Hong Kong February – March 2016.

 

PP-CVP-HKG-0147

Lipitor
健壓樂<sup>™</sup> Norvasc<sup>™</sup>

通用名稱: 苯磺酸氨氯地平 (Amlodipine Besylate)

劑量: 2.5毫克、5毫克、10毫克

晨早血壓波動容易增加心腦血管危機1!健壓樂™為鈣通道阻斷劑,獲英國國家健康與照顧卓越研究院2及歐洲心臟病協會3推薦。每日1次4,藥效超過24小時4,適合關注血壓人士服用。健壓樂™擁有超過20年的臨床經驗5,於同類血壓藥物全球銷量No.16,是你的晨早好拍檔。

 

資料來源
  1. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension 2010;56:765-773.
  2. National Institute for Health and Clinical Excellence. Hypertension in adults: diagnosis and management. Available at: nice.org.uk/guidance/cg127. Accessed February 2017.
  3. Mancia G, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013;34:2159-2219.
  4. Rothwell PM, et al. Effects of beta blockers and calcium-channel blockers on within individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-480.
  5. Norvasc™ (amlodipine) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version July 2015.
  6. HKAPI Data 2003-2015. Accessed November 2015.
  7. IMS data. Third Quarter November 2016.

 

CVS17053C/MAR

Norvasc
確健心<sup>® </sup> Caduet<sup>® </sup>

通用名稱: 阿托伐他汀鈣 (Atorvastatin Calcium) /苯磺酸氨氯地平 (Amlodipine Besylate)

劑量: 10/5毫克、20/5毫克、10/10毫克、20/10毫克

確健心® Caduet® 結合了膽固清® Lipitor® 和健壓樂™ Norvasc™,適合同時關注膽固醇及血壓人士服用,全面減低患者的心血管風險1,2

 

資料來源
  1. CADUET® (amlodipine/atorvastatin) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version December 2017.
  2. Sever P, et al. Eur Heart J. 2006;27:2982-2988.

PP-CAD-HKG-0001

Caduet
Inspra<sup>™</sup>

通用名稱: 依普利酮 (Eplerenone)

劑量: 25毫克、50毫克

Inspra™ 屬於鹽皮質激素受體拮抗劑的一種1,可輔助紐約心臟協會心臟功能第二級的慢性收縮期心臟衰竭及左心室收縮功能障碍(LVEF≤30%)患者的標準治療,以降低心血管死亡風險和因心臟衰竭而導致住院治療的次數1。Inspra™亦適用於治療輕度和中度原發性高血壓 ,可於服用其他治療高血壓藥物仍未能受控或不適合的患者作混合式治療1。Inspra™受歐洲心臟病協會(ESC/ESH)2,3及美國心臟學院基金會/美國心臟協會(ACC/AHA)4,5推薦。 

資料來源
  1. Inspra™ (eplerenone) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version August 2017.
  2. McMurray J, Adamopoulos S, Anker S et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-1847. doi:10.1093/eurheartj/ehs104
  3. Mancia G, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
  4. Whelton PK, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017 [Epub ahead of print].
  5. Yancy C, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013;128(16). doi:10.1161/cir.0b013e31829e8776

PP-INS-HKG-0012

Inspra
Revatio<sup>™</sup>

通用名稱: 西地那非 (Sildenafil)

劑量: 20毫克

Revatio™是一種口服藥物,專門針對關注肺動脈血壓患者,或可提升患者的運動能力1。此藥物必須由有經驗的醫生處方。

資料來源
  1. Revatio™ (sildenafil) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version Version December 2017.

 

PP-CVP-HKG-0148

Revatio